Back to Search Start Over

Is a treat-to-target approach to lipid-lowering therapy appropriate in patients with chronic kidney disease? A prospective French cohort study

Authors :
Sophie Liabeuf
Epiphane Kolla
Denis Fouque
Luc Frimat
Eric Bruckert
Jean Ferrières
Roberto Pecoits-Filho
Oriane Lambert
Christian Combe
Ziad A. Massy
Maurice Laville
Bénédicte Stengel
Nicolas Mansencal
Centre de recherche en épidémiologie et santé des populations (CESP)
Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay
Hôpital Ambroise Paré [AP-HP]
Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3)
Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées
Service de cardiologie [Toulouse]
Hôpital de Rangueil
CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse]
Institut E3M [CHU Pitié-Salpêtrière]
CHU Pitié-Salpêtrière [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Service de cardiologie et maladies vasculaires [CHU Ambroise Paré]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Ambroise Paré [AP-HP]
Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN)
Université Claude Bernard Lyon 1 (UCBL)
Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)
Association pour l'Utilisation du Rein Artificiel Région Lyonnaise [Lyon] (AURAL)
Adaptation, mesure et évaluation en santé. Approches interdisciplinaires (APEMAC)
Université de Lorraine (UL)
Service de Néphrologie [CHRU Nancy]
Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)
Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS)
Hospices Civils de Lyon (HCL)
Bioingénierie tissulaire (BIOTIS)
Université de Bordeaux (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Service de Néphrologie-transplantation-dialyse [Bordeaux]
CHU Bordeaux [Bordeaux]
Arbor Research Collaborative for Health
CHU Amiens-Picardie
Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV)
Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie
CKD-REIN Collaborators
Université Toulouse III - Paul Sabatier (UT3)
Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)
Service Cardiologie [CHU Toulouse]
Pôle Cardiovasculaire et Métabolique [CHU Toulouse]
Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)
CarMeN, laboratoire
Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Source :
Journal of Nephrology, Journal of Nephrology, Italian Society of Nephrology/Springer, 2021, 34 (5), pp.1467-1477. ⟨10.1007/s40620-021-01086-y⟩, Journal of Nephrology, 2021, 34 (5), pp.1467-1477. ⟨10.1007/s40620-021-01086-y⟩
Publication Year :
2021
Publisher :
HAL CCSD, 2021.

Abstract

International audience; BACKGROUND: Whereas European guidelines recommend adjusting lipid-lowering therapy (LLT) to meet prespecified targets ('treat-to-target') for low-density lipoprotein cholesterol (LDL-C), other guidelines do not ('fire and forget'). In a large observational prospective cohort, we sought to evaluate which strategy could be associated with better cardiovascular outcomes in chronic kidney disease (CKD). METHODS: In CKD-REIN, patients (CKD stages 3 and 4) on LLT were categorized according to achievement of LDL-C targets for high and very high cardiovascular risk (\textless 2.6 and \textless 1.8 mmol/L, respectively) at baseline. Primary outcome was fatal/non-fatal atheromatous cardiovascular disease (CVD). Secondary outcomes were non-atheromatous CVD, atheromatous or non-atheromatous CVD, and major adverse cardiovascular events. RESULTS: The population comprised 1521 patients (68 ± 12 years, 31% women, mean estimated glomerular filtration rate [eGFR] 35 mL/min/1.73 m(2)). Overall, 523 (34%) met their LDL-C targets at baseline. Median follow-up was 2.9 years (interquartile range 2.2-3.0). Incidence rates per 100 patient-years were 6.2% (95% confidence interval [CI] 5.5-7.0) for atheromatous CVD, 9.2% (8.3-10.1) for non-atheromatous CVD, 15.2% (14.0-16.4) for atheromatous/non-atheromatous CVD, and 6.3% (5.5-7.1) for major adverse cardiovascular events. Corresponding rates in patients who achieved targets were 6.6%, 9.8%, 16.1%, and 6.3%, respectively. Target achievement was not associated with risk of fatal/non-fatal atheromatous CVD (adjusted hazard ratio 1.04, 95% CI 0.76-1.44, p = 0.77) or fatal/non-fatal atheromatous or non-atheromatous CVD (0.98, 0.78-1.23, p = 0.91). CONCLUSIONS: These findings do not appear to support a treat-to-target approach in CKD patients on LLT, and may favor the hypothesis of an advantage of fire-and-forget. Randomized trials are needed to confirm this theory.

Details

Language :
English
ISSN :
11218428 and 17246059
Database :
OpenAIRE
Journal :
Journal of Nephrology, Journal of Nephrology, Italian Society of Nephrology/Springer, 2021, 34 (5), pp.1467-1477. ⟨10.1007/s40620-021-01086-y⟩, Journal of Nephrology, 2021, 34 (5), pp.1467-1477. ⟨10.1007/s40620-021-01086-y⟩
Accession number :
edsair.doi.dedup.....b22a6e3366caa8199bebf6f9e1b08c01